BareBaby™ · Nutralac Premium

For healthcare professionals

This page contains scientific and technical information intended for registered healthcare professionals. It is not advertising and is not intended for the general public. Infant milk substitute should be used only on the advice of a healthcare professional.

This information is restricted to healthcare professionals. For product and preparation information, please refer to the product label.
MOTHER'S MILK IS BEST FOR YOUR BABY · Scientific information for healthcare professionals · Not for public distribution
BareBaby™ · Nutralac Premium · Clinical & scientific information

The evidence behind the formulation

A reference summary of the composition of Nutralac Premium whole-milk infant formula and the peer-reviewed literature relevant to each ingredient and formulation choice. For healthcare professionals.

Formulation philosophy

Built to the standard, refined by choice

Nutralac Premium is formulated to the composition for infant formula set out in the FSS (Foods for Infant Nutrition) Regulations, 2020 and Codex STAN 72-1981, and tested to IS 14433. Within those limits, the formulation uses a whole-milk base with retained milk fat, lactose as the sole carbohydrate, a palm-oil-free fat blend, vegetarian algal DHA with fungal ARA, and a GOS/FOS + L. reuteri synbiotic.

The references below are evidence for the ingredients and formulation choices, not claims that this product reproduces any individual study outcome. Some cited trials are null or report dose-dependent effects (e.g. iron fortification, choline, and probiotic colic in community settings) and are included for balance. No head-to-head clinical trial of Nutralac Premium against another product exists. Citations have been checked against published records; PMID/DOI identifiers are given where available.
Sourcing, manufacturing & traceability

From a known origin, tested every batch

Where the milk comes from, who makes the formula, and how each batch is tested and traced.

Milk sourced directly from local farmers

Milk is sourced directly from local dairy farmers rather than pooled from the open commodity market, keeping the origin of the milk known.

Manufactured by Nutrimed

Produced by Nutrimed, a dairy-nutrition manufacturer operating since 2011 and built on a family dairy business of more than three decades, with roughly 28 years of R&D in baby foods and dairy nutrition. Nutrimed manufactures at ISO 22000, HACCP and GMP certified, FSSAI-licensed and NABL-lab-tested facilities in Faridabad and Ballabhgarh (Haryana), and already produces infant milk formula, whole- and skimmed-milk powder and butter. Its founder, a former NDRI food scientist, is credited by the company with earlier formulations including Complan and Farex.

Batch testing: microbiology & heavy metals

Every batch is tested for microbiological parameters (including Cronobacter and Salmonella) and for heavy metals (lead, arsenic, cadmium, mercury) against the IS 14433 specification before release.

Certificate of analysis per batch

A certificate of analysis is issued for every production batch and is accessible via the QR code on the tin.

Traceable to source

Each functional ingredient carries a named origin, so a finished tin can be traced back through its ingredients to their roots.

Comparison

Generic infant formula vs Nutralac Premium

A technical comparison of common category practice against the Nutralac Premium formulation. “Generic formula” describes typical practice and varies by brand and product; this is not a claim against any named product.

ParameterGeneric infant formulaNutralac Premium
Milk baseSkimmed milk reconstituted with vegetable oilsWhole milk with retained milk fat + butter oil
CarbohydrateLactose, often with maltodextrin or corn-syrup solidsLactose only
Fat blendMay include palm oil / palm oleinPalm-free: sunflower, coconut, flaxseed
DHA sourceFish-derived or algal; ARA variesAlgal DHA (vegetarian) + fungal ARA
Gut supportUsually a prebiotic or a probioticGOS + FOS prebiotics and L. reuteri DSM 17938
Milk sourcingPooled / commodity milk powderDirect from local farmers
Testing & traceabilityStatutory minimumPer-batch microbiology + heavy metals; COA per batch; ingredient-level traceability
Added colours / flavoursPermitted; varies by productNone
Per-ingredient rationale

The composition, ingredient by ingredient

Each ingredient with its role in the formula and the relevant evidence base (reference numbers refer to the library below).

Whole milk & milk fat

Built on whole milk solids with added anhydrous milk fat (butter oil), rather than skimmed milk reconstituted with vegetable oils. This retains naturally occurring milk fat and the fat-soluble vitamins and phospholipids associated with it.

Evidence: refs 7–9

Protein & whey

Demineralised whey (90% demineralised) with skimmed milk and whey protein concentrate gives a whey-predominant protein at a level within the standard. Protein quantity in infancy is associated with later weight trajectory.

Evidence: refs 10–14

Carbohydrate: lactose

Lactose is the sole carbohydrate — no maltodextrin, corn-syrup solids or sucrose. Lactose is the physiological, low-glycaemic milk sugar; glucose polymers are permitted but add nothing nutritionally over lactose.

Evidence: refs 15–18

Fats: a palm-free blend

Cold-pressed sunflower oil (linoleic acid), coconut oil and encapsulated flaxseed oil (α-linolenic acid) supply the essential fatty acids the standard requires, without palm oil or palm olein.

Evidence: refs 19–24

DHA & ARA

Docosahexaenoic acid from algae (Schizochytrium sp.) and arachidonic acid from fungus (Mortierella alpina), formulated in balance, as a permitted optional addition.

Evidence: refs 25–29, 30–32

Prebiotics (GOS + FOS)

Galacto- and fructo-oligosaccharides as non-digestible prebiotic fibres.

Evidence: refs 33–39

Probiotic & synbiotic

Lactobacillus reuteri DSM 17938 as a strain-specific probiotic; together with GOS/FOS it constitutes a synbiotic.

Evidence: refs 40–48

5′-Nucleotides

CMP, UMP, AMP, IMP and GMP — the nucleotide profile present in milk.

Evidence: refs 49–53

Choline

Added at the level set by the standard; choline is a conditionally essential nutrient present in breast milk.

Evidence: refs 54–57

Taurine

A conditionally essential amino acid added to the level the standard specifies.

Evidence: refs 58–59

L-carnitine

A cofactor for mitochondrial fatty-acid oxidation, present in both breast milk and infant formula.

Evidence: refs 60–61

Inositol

Myo-inositol, a micronutrient present at high concentration in breast milk.

Evidence: refs 62–63

Vitamins & minerals

The full complement of vitamins and minerals, each dosed within the standard's min–max window.

Evidence: refs 64–68
What Nutralac Premium leaves out — and why

The rationale for exclusions

Palm oil, added sugars and maltodextrin are all permitted and safe under Codex and FSSAI. These are optimisation choices toward the composition of milk, not safety claims.

No palm oil or palm olein

Pancreatic lipase is sn-1,3-specific. In vegetable palm olein most palmitic acid sits at the sn-1 and sn-3 positions, so digestion releases it as free palmitic acid, which binds luminal calcium into insoluble calcium–palmitate soaps lost in stool — carrying both fat and calcium with it. In human milk and in milk fat a larger share of palmitate is esterified at sn-2, where it is absorbed as 2-monopalmitin and does not form soaps; because Nutralac Premium is whole-milk based and palm-free, its fat carries more sn-2 palmitate than a palm-olein blend. A meta-analysis of 9 RCTs found palm-free formulas give significantly softer stools (pooled mean difference −0.355); stool frequency and growth do not differ. Palm oil is permitted and safe under Codex and FSSAI — this is a tolerability and absorption optimisation, not a safety claim.

Evidence: refs 69–82, 19–24

No sucrose or added free sugars

Lactose, the intrinsic sugar of milk, is the sole carbohydrate. There is no physiological requirement for free sugars in infancy. Infants are born with an innate sweet preference that is biologically maximal in infancy, and sweetening formula amplifies that drive at its most plastic window. Free sugars — with sucrose the paradigmatic cariogenic sugar — are linked to dental caries on moderate-quality evidence, and added sugars in infancy (largely formula-delivered) are associated with rapid early weight gain. ESPGHAN states that in infant formula lactose is the preferred sugar and sucrose, glucose and fructose are not permitted; WHO's free-sugar limits explicitly exempt milk lactose; Codex restricts added sucrose and fructose.

Evidence: refs 69–82

No maltodextrin or corn-syrup solids

Glucose polymers — maltodextrin, corn-syrup or glucose-syrup solids — are permitted co-carbohydrates (Codex lists them alongside lactose as “preferred”), used mainly for cost, lower sweetness and osmolality control rather than for any infant benefit. Lactose is low-glycaemic (GI ~46); a maltodextrin-based follow-on formula measured a glycaemic index of 63. The one direct lactose-vs-corn-syrup-solids infant trial found no difference in postprandial glucose or insulin, so the case rests on a large WIC cohort (>15,000 children) in which corn-syrup-solids formula carried a modest, dose-dependent higher childhood obesity risk (relative risk ~1.07–1.16), plus associations with rapid infant weight gain and a shifted gut microbiota. Mechanistic work on pathogen adhesion and mucus-barrier breakdown is in-vitro and animal only. Maltodextrin is GRAS and safe; the argument is optimisation toward the milk sugar, not toxicity.

Evidence: refs 69–82
Quality & safety

Testing and specification

ParameterApproach
SpecificationTested to IS 14433:2022 (Infant Milk Substitutes) and FSS (Foods for Infant Nutrition) Regulations, 2020
Heavy metalsBatch testing by ICP-MS (lead, arsenic, cadmium, mercury) to IS 14433 specification limits
MicrobiologyCronobacter and Salmonella absent; Enterobacteriaceae tested each batch
ManufacturerNutrimed, Faridabad (Haryana) · FSSAI 10821003000252
Certificate of analysisAvailable per batch via the on-pack QR code
Reference library

82 peer-reviewed references

Grouped by ingredient and formulation topic. Standards and expert-group documents are included alongside clinical studies. Checked against published records; PMID/DOI given where available.

Standards & composition [1–6]

  1. 1FSSAI. Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020. New Delhi.
  2. 2Codex Alimentarius. Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants (CXS 72-1981, rev. 2007, amended 2015). FAO/WHO.
  3. 3Koletzko B, et al. Global standard for the composition of infant formula: ESPGHAN coordinated international expert group. J Pediatr Gastroenterol Nutr. 2005;41(5):584–599. PMID 16254515.
  4. 4Bureau of Indian Standards. IS 14433:2022 — Infant Milk Substitutes — Specification. BIS.
  5. 5ICMR–National Institute of Nutrition. Nutrient Requirements for Indians (RDA & EAR). 2020.
  6. 6WHO/FAO. Safe preparation, storage and handling of powdered infant formula: guidelines. Geneva; 2007.

Whole milk & milk fat [7–9]

Nutralac Premium retains native milk fat via whole milk solids and anhydrous milk fat (butter oil). These references concern milk-fat / MFGM composition; Nutralac is not an added-MFGM product.
  1. 7Timby N, et al. Neurodevelopment, nutrition and growth until 12 mo in infants fed a formula supplemented with bovine milk fat globule membranes: RCT. Am J Clin Nutr. 2014;99(4):860–868. PMID 24500150.
  2. 8Hernell O, Timby N, Domellöf M, Lönnerdal B. Clinical benefits of milk fat globule membranes for infants and children. J Pediatr. 2016;173(Suppl):S60–S65. doi:10.1016/j.jpeds.2016.02.077.
  3. 9Billeaud C, et al. Safety and tolerance of milk-fat-globule-membrane-enriched infant formulas: multicentre RCT. Clin Med Insights Pediatr. 2014;8:51–60. doi:10.4137/CMPed.S16962.

Protein level & whey quality [10–14]

Rationale for a whey-predominant design using demineralised whey.
  1. 10Koletzko B, et al. Lower protein in infant formula is associated with lower weight up to age 2 y: RCT. Am J Clin Nutr. 2009;89(6):1836–1845. PMID 19386747.
  2. 11Weber M, et al. Lower protein content in infant formula reduces BMI and obesity risk at school age: follow-up of an RCT. Am J Clin Nutr. 2014;99(5):1041–1051. PMID 24622805.
  3. 12Totzauer M, et al. Protein intake in infancy and adiposity to age 11 y (European Childhood Obesity Trial). Pediatr Obes. 2022. PMID 36355369.
  4. 13Fleddermann M, et al. Infant formula composition and anthropometry at 4 years (BeMIM): follow-up RCT. PLoS One. 2018;13(7):e0199859.
  5. 14Tinghäll Nilsson U, et al. Low-protein formulas with α-lactalbumin-enriched or glycomacropeptide-reduced whey: RCT. Nutrients. 2023;15(4):1010. PMID 36839368.

Carbohydrate: lactose vs glucose polymers [15–18]

Rationale for lactose as the sole carbohydrate rather than maltodextrin or corn-syrup solids.
  1. 15Fleddermann M, Koletzko B, et al. Low-glycaemic-index vs maltodextrin follow-on formula: postprandial response and calculated glycaemic index in infants (maltodextrin formula GI 63). PLoS One. 2016;11(3):e0151614. doi:10.1371/journal.pone.0151614.
  2. 16Slupsky CM, Hernell O, Lönnerdal B, West AA, et al. Postprandial glucose and insulin response to lactose- vs corn-syrup-solids infant formula vs breastfeeding: RCT (no AUC difference). Sci Rep. 2017;7:3640. doi:10.1038/s41598-017-03975-4.
  3. 17Stephen A, et al. The role and requirements of digestible dietary carbohydrates in infants and toddlers. Eur J Clin Nutr. 2012;66(7):765–779. PMID 22473042.
  4. 18Goran MI, et al. (Children's Hospital Los Angeles). Infant-formula carbohydrate type and glycaemic variability vs human milk: controlled study. Am J Clin Nutr. 2026 (in press).

Fats & essential fatty acids [19–24]

Rationale for a palm-oil-free blend (sunflower, coconut, flaxseed) supplying linoleic and α-linolenic acids.
  1. 19Perspective: Moving toward desirable linoleic acid content in infant formula. Adv Nutr. 2021;12(6):2085–2098. PMID 34265035.
  2. 20Einerhand AWC, Mi W, Haandrikman A, Sheng XY, Calder PC. The impact of linoleic acid on infant health in the absence or presence of DHA in infant formulas. Nutrients. 2023;15(9):2187. doi:10.3390/nu15092187.
  3. 21Béghin L, et al. Growth, stool consistency and bone mineral content in term infants fed sn-2-palmitate-enriched starter formula: RCT. Clin Nutr. 2019;38(3):1023–1030. PMID 29903473.
  4. 22Sheng XY, et al. A2 β-casein formula with high sn-2 palmitate and casein phosphopeptides: RCT. Front Nutr. 2024;11:1442584. doi:10.3389/fnut.2024.1442584.
  5. 23Lasekan JB, Hustead DS, Masor M, Murray R. Impact of palm olein in infant formulas on stool consistency and frequency: meta-analysis of RCTs. Food Nutr Res. 2017;61(1):1330104. doi:10.1080/16546628.2017.1330104.
  6. 24Litmanovitz I, et al. High β-palmitate formula and bone strength in term infants: RCT. Calcif Tissue Int. 2013;92(1):35–41. PMID 23179103.

DHA & ARA [25–29]

  1. 25Tian A, et al. Effects of different proportions of DHA and ARA on cognitive development in infants: meta-analysis. Nutrients. 2025;17(6):1091. doi:10.3390/nu17061091.
  2. 26DHA and ARA supplementation and neurodevelopment in term infants: results of randomized controlled trials. J Pediatr. 2003;143(4 Suppl):S17–S25. PMID 14597910.
  3. 27Birch EE, et al. Visual acuity and cognitive outcomes at 4 years: RCT of LCPUFA-supplemented infant formula. Early Hum Dev. 2007;83(5):279–284. PMID 17240089.
  4. 28Jasani B, Simmer K, Patole S, Rao S. Long-chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev. 2017;3:CD000376. doi:10.1002/14651858.CD000376.pub4. PMID 28281303.
  5. 29Hadley KB, Ryan AS, Forsyth S, Gautier S, Salem N Jr. The essentiality of arachidonic acid in infant development. Nutrients. 2016;8(4):216.

Algal DHA — source & safety [30–32]

  1. 30Hammond BG, et al. Safety assessment of DHA-rich microalgae from Schizochytrium sp. Regul Toxicol Pharmacol. 2001;33(3):356–362.
  2. 31EFSA NDA Panel (Turck D, et al.). Safety of oil from Schizochytrium sp. for use in infant and follow-on formula. EFSA J. 2020;18:6242. doi:10.2903/j.efsa.2020.6242.
  3. 32US FDA. GRAS Notice Inventory — DHA algal oil from Schizochytrium sp., infant-formula uses. fda.gov.

Prebiotics (GOS + FOS) [33–39]

  1. 33Moro G, et al. Colon microflora in infants fed formula with galacto- and fructo-oligosaccharides: more like breast-fed infants. J Pediatr Gastroenterol Nutr. 2005;40(1):36–42. PMID 15625424.
  2. 34Bakker-Zierikzee AM, et al. GOS/FOS or B. animalis and intestinal microflora in infants. Br J Nutr. 2005;94(5):783–790. PMID 16277782.
  3. 35Bruzzese E, et al. A formula containing GOS/FOS prevents intestinal and extra-intestinal respiratory tract infections. Clin Nutr. 2009;28(2):156–161. PMID 19231042.
  4. 36Kadim M, et al. Gastrointestinal health and immunity of milk formula supplemented with scGOS/lcFOS (9:1): systematic review with meta-analysis. Pediatr Gastroenterol Hepatol Nutr. 2025;28(1):1–18. doi:10.5223/pghn.2025.28.1.1.
  5. 37Fanaro S, et al. Galacto-oligosaccharides are bifidogenic and safe at weaning: double-blind randomized multicentre study. J Pediatr Gastroenterol Nutr. PMID 21593649.
  6. 38Agostoni C, et al. Prebiotic oligosaccharides in dietetic products for infants: commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2004;39(5):465–473.
  7. 39Closa-Monasterolo R, et al. Safety and efficacy of inulin and oligofructose supplementation in infant formula: RCT. Clin Nutr. 2013;32(6):918–927.

Probiotic & synbiotic (L. reuteri DSM 17938) [40–48]

GOS/FOS plus L. reuteri DSM 17938 constitutes a synbiotic. Colic evidence is strain-specific and strongest in breastfed infants; one large community RCT was null.
  1. 40Savino F, et al. Lactobacillus reuteri DSM 17938 in infantile colic: RCT. Pediatrics. 2010;126(3):e526–e533. PMID 20713478.
  2. 41Szajewska H, et al. L. reuteri DSM 17938 for infantile colic in breastfed infants: RCT. J Pediatr. 2013;162(2):257–262. PMID 22981952.
  3. 42Chau K, et al. Probiotics for infantile colic: RCT of L. reuteri DSM 17938. J Pediatr. 2015;166(1):74–78. PMID 25444531.
  4. 43Sung V, et al. Treating infant colic with L. reuteri: double-blind, placebo-controlled RCT (no benefit in community setting). BMJ. 2014;348:g2107. PMID 24690625. doi:10.1136/bmj.g2107.
  5. 44Indrio F, et al. Prophylactic L. reuteri DSM 17938 for colic, regurgitation and constipation: RCT. JAMA Pediatr. 2014;168(3):228–233. PMID 24424513.
  6. 45Xu M, et al. L. reuteri DSM 17938 for infantile colic: meta-analysis of RCTs. PLoS One. 2015;10(10):e0141445. PMID 26509502.
  7. 46Braegger C, et al. Supplementation of infant formula with probiotics and/or prebiotics: systematic review and comment by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2011;52(2):238–250.
  8. 47Mugambi MN, et al. Synbiotics, probiotics or prebiotics in infant formula for full-term infants: systematic review. Nutr J. 2012;11:81. PMID 23035863.
  9. 48Ferro LE, et al. Effects of prebiotics, probiotics and synbiotics on the infant gut microbiota and other health outcomes: systematic review. Crit Rev Food Sci Nutr. 2023;63(22):5620–5642. PMID 37667870.

Nucleotides [49–53]

  1. 49Pickering LK, et al. Modulation of the immune system by human milk and infant formula containing nucleotides. Pediatrics. 1998;101(2):242–249. PMID 9445498.
  2. 50Schaller JP, et al. Effect of dietary ribonucleotides on infant immune status. Part 1: humoral responses. Pediatr Res. 2004;56(6):883–890.
  3. 51Hawkes JS, et al. Effect of dietary nucleotide supplementation on growth and immune function in term infants: RCT. Eur J Clin Nutr. 2006;60(2):254–264. doi:10.1038/sj.ejcn.1602310.
  4. 52Yau KI, et al. Effect of nucleotides on diarrhea and immune responses in healthy term infants in Taiwan. J Pediatr Gastroenterol Nutr. 2003;36(1):37–43. PMID 12499994.
  5. 53Carver JD, et al. Dietary nucleotide effects upon immune function in infants. Pediatrics. 1991;88(2):359–363.

Choline [54–57]

  1. 54Cheatham CL, et al. Phosphatidylcholine supplementation in pregnant women consuming moderate-choline diets does not enhance infant cognitive function: RCT (null). Am J Clin Nutr. 2012;96(6):1465–1472. PMID 23134891.
  2. 55Caudill MA, et al. Maternal choline supplementation in the third trimester improves infant information processing speed: RCT. FASEB J. 2018;32(4):2172–2180. PMID 29217669.
  3. 56Bahnfleth CL, et al. Prenatal choline supplementation improves child sustained attention: 7-year follow-up of an RCT. FASEB J. 2022;36(1):e22054. PMID 34962672.
  4. 57Obeid R, et al. Association between maternal choline, fetal brain development and child neurocognition: systematic review and meta-analysis. Adv Nutr. 2022;13(6):2445–2457. PMID 36041182.

Taurine [58–59]

  1. 58Chesney RW, et al. The role of taurine in infant nutrition. Adv Exp Med Biol. 1998;442:463–476. PMID 9635063.
  2. 59Verner A, Craig S, McGuire W. Effect of taurine supplementation on growth and development in preterm or low-birth-weight infants. Cochrane Database Syst Rev. 2007;(4):CD006072. doi:10.1002/14651858.CD006072.pub2.

L-carnitine [60–61]

  1. 60Cairns PA, Stalker DJ. Carnitine supplementation of parenterally fed neonates. Cochrane Database Syst Rev. 2000;(4):CD000950. doi:10.1002/14651858.CD000950.
  2. 61Mo S, et al. L-carnitine: new perspectives on the management of preterm infants. Front Nutr. 2025;12:1508441. doi:10.3389/fnut.2025.1508441.

Inositol [62–63]

  1. 62Howlett A, Ohlsson A, Plakkal N. Inositol in preterm infants at risk for or having respiratory distress syndrome. Cochrane Database Syst Rev. 2019;7:CD000366. doi:10.1002/14651858.CD000366.pub4.
  2. 63Myo-inositol, a human-milk nutrient, promotes synapse development in the developing brain. Proc Natl Acad Sci USA. 2023;120(29):e2221413120. PMID 37433002. doi:10.1073/pnas.2221413120.

Vitamins & minerals (iron, vitamin D) [64–68]

  1. 64Iglesias Vázquez L, et al. Does fortified milk with high iron dose improve neurodevelopment of healthy infants? RCT (null). BMC Pediatr. 2019;19:315.
  2. 65Morley R, et al. Iron-fortified follow-on formula from 9 to 18 months improves iron status but not development or growth: RCT. Arch Dis Child. 1999;81(3):247–252.
  3. 66Tan ML, Abrams SA, Osborn DA. Vitamin D supplementation for term breastfed infants to prevent deficiency and improve bone health. Cochrane Database Syst Rev. 2020;12:CD013046. doi:10.1002/14651858.CD013046.pub2.
  4. 67O'Callaghan KM, et al. Vitamin D in breastfed infants: systematic review of alternatives to daily supplementation. Adv Nutr. 2020;11(1):144–159. PMID 31552417.
  5. 68Abiramalatha T, et al. Comparative efficacies of vitamin D supplementation regimens in infants: systematic review and network meta-analysis. Br J Nutr. 2024. doi:10.1017/S0007114524001685.

Rationale for exclusions — palm oil, sugars, maltodextrin [69–82]

  1. 69Padial-Jáudenes M, et al. Physiological impact of palm olein or palm oil in infant formulas: review of clinical evidence. Nutrients. 2020;12(12):3676. PMID 33260586. doi:10.3390/nu12123676.
  2. 70Koo WWK, Hockman EM, Dow M. Palm olein in the fat blend of infant formulas: effect on intestinal absorption of calcium and fat, and bone mineralization. J Am Coll Nutr. 2006;25(2):117–122. doi:10.1080/07315724.2006.10719521.
  3. 71Yu Z, et al. [Effects of infant formula containing palm oil on nutrient absorption and defecation in infants: a meta-analysis]. 2009 (Chinese). PMID 20193141.
  4. 72Bar-Yoseph F, Lifshitz Y, Cohen T, et al. A high-sn-2-palmitate formula reduces fatty-acid soaps and stool calcium loss in term infants: RCT. J Pediatr Gastroenterol Nutr. 2016;62(2):341–347. PMID 26334255.
  5. 73Nowacki J, et al. High sn-2 palmitate with oligofructose reduces stool soaps and hardness in term infants: RCT. Nutr J. 2014;13:105. doi:10.1186/1475-2891-13-105.
  6. 74Fidler Mis N, et al. (ESPGHAN Committee on Nutrition). Sugar in infants, children and adolescents: a position paper. J Pediatr Gastroenterol Nutr. 2017;65(6):681–696. PMID 28922262.
  7. 75Mennella JA. Ontogeny of taste preferences: basic biology and implications for health. Am J Clin Nutr. 2014;99(3):704S–711S. PMID 24452237.
  8. 76Moynihan PJ, Kelly SA. Effect on caries of restricting sugars intake: systematic review to inform WHO guidelines. J Dent Res. 2014;93(1):8–18. PMID 24323509.
  9. 77WHO. Guideline: Sugars intake for adults and children. Geneva: World Health Organization; 2015.
  10. 78Anderson CE, Whaley SE, Goran MI. Lactose-reduced infant formula with corn-syrup solids and obesity risk among WIC participants. Am J Clin Nutr. 2022;116(4):1002–1009. PMID 35998087. doi:10.1093/ajcn/nqac173.
  11. 79Kong KL, et al. Association between added sugars from infant formulas and rapid weight gain in US infants and toddlers. J Nutr. 2021;151(6):1572–1580. PMID 33880550.
  12. 80Jones RB, Berger PK, et al. Lactose-reduced infant formula with added corn-syrup solids is associated with a distinct gut microbiota in infants. Gut Microbes. 2020;12(1):1813534. PMID 32887539.
  13. 81Nickerson KP, McDonald C. Adherent-invasive Escherichia coli adhesion is enhanced by the dietary polysaccharide maltodextrin (in vitro / human tissue). PLoS One. 2012;7(12):e52132. PMID 23251695.
  14. 82The dietary polysaccharide maltodextrin promotes Salmonella survival and mucosal colonization in mice (animal). PLoS One. 2014;9(7):e101789. PMID 25000398.